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Cerebral tuberculomas are a rare and serious form of tuberculosis (TB) due to the haematogenous spread
of Mycobacterium Tuberculosis (MT). Symptoms and radiologic features are nonspeciﬁc, leading some-
times to misdiagnosis. Anti-TB drugs are essential for the successful treatment of cerebral tuberculomas
but there is no agreement regarding the duration of therapy.
The authors present a case of a 55 years old male, presented to the emergency roomwith sudden onset
of diplopia. Cerebral computerized tomography revealed multiple brain lesions, with contrast
enhancement and peri-lesional oedema. The patient was HIV negative and because of previous malig-
nancy the ﬁrst suspicion was metastatic disease. Cultural exam of the bronchial wash showed MT sen-
sitive to all ﬁrst-line drugs. The patient started antituberculosis treatment with 4 drugs (HRZE) for 2
months, followed by maintenance therapy (HR). Treatment was prolonged for 24 months because at 12th
and 18th months of treatment one of the brain lesions, although signiﬁcantly smaller, still showed
contrast enhancement.
Even though it is not clear if contrast enhancement lesions represent active lesions or just inﬂam-
mation, continuing treatment until total resolution of the tuberculomas is probably prudent.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Background
Central nervous system (CNS) tuberculosis (TB) is a serious form
of TB, due to haematogenous spread ofMycobacterium tuberculosis
(MT). Manifesting as meningitis, cerebritis and tuberculous ab-
scesses or tuberculomas, it occurs in approximately 1% of all pa-
tients with TB, affecting disproportionately children and
immunosuppressed patients. Other risk factors include malnutri-
tion, alcoholism and malignancies.1
Intracranial tuberculomas are the least common presentation of
CNS TB, found in 1% of these patients.2 They are multiple in only
15%e33% of the cases.3
Tuberculomas often present with symptoms and signs of focal
neurological deﬁcit without evidence of systemic disease.4 The
radiologic features are also nonspeciﬁc and differential diagnosis
includes malignant lesions, sarcoidosis, pyogenic abscess, toxo-
plasmosis and cysticercosis.1,4,5teiro).
-NC-ND license.It is universally accepted that anti-TB drugs are essential for the
successful treatment of intracranial tuberculomas but there is no
agreement regarding the duration of therapy.3,6,7
2. Case report
A 55 years old white male, ex-smoker for 19 years (6 pack-
years), working as an air conditioning installer, came to the Emer-
gency Room in May 2010 with sudden onset of diplopia. He also
complained of headache, loss of weight (about 10% over the last
month) and of back pain over the last year, that he thought to be
related with an accident. He denied any respiratory symptom or
other.
His medical history included a right colon cancer, treated with
surgery and chemotherapy 20 years ago (he had abandoned follow-
up after 10 years), and pulmonary TB 4 years ago, treated with 2
months of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
(HRZE) follow by 4 months of Isoniazid and Rifampicin (HR) under
directly observed therapy (DOT) e after that he went abroad and
missed follow-up. He was not on any medication and denied any
allergies.
On examination the patient was underweight and walked with
difﬁculty because of the diplopia. His physical examination was
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tomography (CT) revealed multiple brain lesions, with contrast
enhancement and peri-lesional oedema.
He was admitted for investigation and treatment. Brain mag-
netic resonance imaging (MRI) conﬁrmed 4 space occupying le-
sions with central necrosis, irregular outlines with peripheral
contrast enhancing and moderate peri-lesional oedema (Fig. 1).Fig. 1-. Brain MR before treatment: 4 space occupying lesions in the brain with central necr
oedema.Lumbar puncture was performed but was not diagnostic (cere-
brospinal ﬂuid was negative for malignant cells or microorgan-
isms). Biochemical analyses such as nucleic acid ampliﬁcation or
adenosine deaminase measurement were not performed. Chest X-
ray was considered normal. Serologies to human immunodeﬁ-
ciency virus (HIV) and toxoplasmosis were negative. Thoracic and
abdominal CT revealed peri-centimetric mediastinal lymph nodes,osis, irregular outlines with peripheral contrast enhancing and moderate peri-lesional
Fig. 2-. Thoracic CT before treatment: peri-centimetric mediastinal lymph nodes;
bilateral lung micronodules and a small condensation area in the right middle lobe
with discrete air bronchogram; lytic lesion at the left 8th rib-vertebral joint.
Fig. 4-. First and last brain MR (after 24 months of treatment): total resolution of the
tuberculomas.
R. Monteiro et al. / Respiratory Medicine Case Reports 9 (2013) 34e3736bilateral pulmonarymicronodules, a small condensation area in the
right middle lobe with discrete air bronchogram and a lytic lesion
at the 8th left rib-vertebral joint (Fig 2). Bronchoscopy showed no
changes in the bronchial tree besides anthracotic plates. Therewere
no malignant cells in the bronchial wash and direct exam was
negative for TB. Endoscopies did not showany sign ofmalignancy. A
positron emission tomography (PET) was performed and revealed
abnormal enhancement in multiple small foci in both lung ﬁelds,
mediastinal and abdominal lymph nodes, bone lesions (3rd and 8th
left ribs and right iliac wing), both adrenals and brain (Fig. 3). The
biopsy of the rib lesion presented only epithelioid granulomas. TB
was conﬁrmed by cultural exam of the bronchial wash that showed
MT sensitive to all ﬁrst-line drugs.Fig. 3-. PET scan: abnormal enhancement in multiple small foci in both lung ﬁeldThe patient had already started corticosteroids (prednisolone
1 mg/kg) at admission for cerebral oedema and antituberculous
treatment was added when TB was found. The patient was dis-
charged but continued treatment with 4 drugs (HRZE) in form ofs; lymph nodes and bone lesions (3rd and 8th left ribs and right iliac wing).
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improvement. After 2 months the patient was completely asymp-
tomatic and treatment was reduced to maintenance therapy with 2
drugs (HR).
Radiologic revaluations were made at 6th, 12th, 18th and 24th
months after the diagnosis and beginning of the treatment. The
lung micronodules and mediastinal lymph nodes remained stable
and some calciﬁed. Bone lesions also stabilized. The brain MRI at
the 18th month of treatment one of the lesions, although signiﬁ-
cantly smaller still showed contrast enhancement so treatment was
prolonged for 24 months. In the last brain MRI no contrast
enhancement lesions were seen (Fig. 4).
3. Discussion
Due to its rarity, nonspeciﬁc symptoms and radiological ﬁnd-
ings, intracranial tuberculomas remain a clinical challenge.
Misdiagnosis of tuberculomas as malignant diseases have been
described in literature.4,5,7,8 Our patient was HIV negative, had a
medical history of malignancy and presented with multiple brain
lesions so the ﬁrst suspicion was also metastatic disease. Tuber-
culomas must however be always included in differential diagnosis
of cerebral space occupying lesions.
As the patient missed follow-up after his ﬁrst TB infection this
may be the case of a reactivation but reinfection is also a possibility
and genotype was not performed.
Regarding treatment, the Center for Disease Control and Pre-
vention recommends 12 months of treatment for CNS TB when the
MT strain is sensitive to all drugs.9 However numerous variables
can affect the response of the disease to therapy and it has been
suggested that treatment duration should be tailored to the
radiological response.6 After 12 months of treatment more than
two-thirds of the patients still have contrast enhancing lesions.
Although it is not clear if this represents an active lesion or just
inﬂammation, continuing treatment is probably prudent. Total
resolution of the tuberculoma is observed when scans demonstrate
no enhancing lesions or only an area of calciﬁcation.6Systemic corticosteroids as adjuvant therapy are indicatedwhen
there is peri-lesional oedema or paradoxical progression during
treatment. Surgical intervention may be necessary in situations
with acute complications or when the diagnosis is not
ensured.2,3,6,10Acknowledgements
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